Cited 0 times in
Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이재승 | - |
dc.contributor.author | 이혜원 | - |
dc.date.accessioned | 2021-12-28T16:44:33Z | - |
dc.date.available | 2021-12-28T16:44:33Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/186780 | - |
dc.description.abstract | It is unclear whether tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is more effective for preventing hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB). In this study, we compared the effectiveness of these two antiviral agents for preventing HCC. We included treatment-naïve CHB patients undergoing antiviral therapy with TDF only (TDF group) or a TAF-based regimen (TAF group) at three academic teaching hospitals from 2012 to 2019. The TAF group included patients receiving TAF as first-line treatment and patients switching from TDF to TAF. Patients with decompensated cirrhosis or HCC at enrollment were excluded. Cumulative probabilities of HCC were assessed using Kaplan-Meier methodology. In total, 2,117 patients were included: 1,832 in the TDF group and 285 in the TAF group. The annual HCC incidence was not significantly different between TDF and TAF groups: 1.66 vs. 1.19 per 100 person-years [PY], respectively (multivariate analysis: adjusted hazard ratio [HR] 0.774 [reference: TDF group]; p = .438). Male, liver cirrhosis, hepatitis B e antigen negativity, Fibrosis-4 index>3.25 and low albumin were independently associated with a higher risk of HCC. Propensity score-matched and inverse probability of treatment weighting analyses yielded similar results: 1.56 vs. 1.19 per 100 PY, respectively (HR 1.175; p = .708) and 1.66 vs. 1.29 per 100 PY, respectively (HR 0.888; p = .446). The risk of HCC development was not significantly different between TDF and TAF groups of CHB patients. Further studies with a larger sample size and longer follow-up are required to validate our results. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Young Youn Cho | - |
dc.contributor.googleauthor | Hyein Lee | - |
dc.contributor.googleauthor | Jae Seung Lee | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Soo Young Park | - |
dc.identifier.doi | 10.1111/jvh.13601 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A05963 | - |
dc.contributor.localId | A03318 | - |
dc.relation.journalcode | J01928 | - |
dc.identifier.eissn | 1365-2893 | - |
dc.identifier.pmid | 34435412 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13601 | - |
dc.subject.keyword | comparison | - |
dc.subject.keyword | hepatocellular carcinoma | - |
dc.subject.keyword | prevention | - |
dc.subject.keyword | tenofovir alafenamide | - |
dc.subject.keyword | tenofovir disoproxil fumarate | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | 김도영 | - |
dc.contributor.affiliatedAuthor | 김범경 | - |
dc.contributor.affiliatedAuthor | 김승업 | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 안상훈 | - |
dc.contributor.affiliatedAuthor | 이재승 | - |
dc.contributor.affiliatedAuthor | 이혜원 | - |
dc.citation.volume | 28 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 1570 | - |
dc.citation.endPage | 1578 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, Vol.28(11) : 1570-1578, 2021-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.